There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Genetics in Anticoagulant Pharmacotherapy
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Recommended
Details
Presenters
Overview
There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
Biomarkers of the Storm: Decoding IRI’s Signature
0.50 credits
<p>Biomarkers of the Storm: Decoding IRI’s Signature</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?